Post-load glucose subgroups and associated metabolic traits in individuals with type 2 diabetes: An IMI-DIRECT study.

Autor: Obura M; Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam University Medical Centre, Location VU University Medical Center, Amsterdam, The Netherlands., Beulens JWJ; Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam University Medical Centre, Location VU University Medical Center, Amsterdam, The Netherlands.; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands., Slieker R; Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam University Medical Centre, Location VU University Medical Center, Amsterdam, The Netherlands.; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands., Koopman ADM; Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam University Medical Centre, Location VU University Medical Center, Amsterdam, The Netherlands., Hoekstra T; Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam University Medical Centre, Location VU University Medical Center, Amsterdam, The Netherlands.; Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Nijpels G; Department of General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, Amsterdam University Medical Centre, Location VU University Medical Center, Amsterdam, The Netherlands., Elders P; Department of General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, Amsterdam University Medical Centre, Location VU University Medical Center, Amsterdam, The Netherlands., Koivula RW; Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Malmö, Sweden.; Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, Oxford, United Kingdom., Kurbasic A; Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Malmö, Sweden., Laakso M; Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland., Hansen TH; The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Cardiology and Endocrinology, Slagelse Hospital, Slagelse, Denmark., Ridderstråle M; The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Hansen T; The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark., Pavo I; Eli Lilly Regional Operations GmbH, Vienna, Austria., Forgie I; Division of Cardiovascular & Diabetes Medicine, Medical Research Institute, University of Dundee, Dundee, United Kingdom., Jablonka B; Sanofi-Aventis Deutschland GmbH, R&D, Frankfurt am Main, Germany., Ruetten H; Sanofi-Aventis Deutschland GmbH, R&D, Frankfurt am Main, Germany., Mari A; Institute of Biomedical Engineering, National Research Council, Padova, Italy., McCarthy MI; Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, Oxford, United Kingdom.; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom., Walker M; Institute of Cellular Medicine (Diabetes), Newcastle University, Newcastle upon Tyne, United Kingdom., Heggie A; Institute of Cellular Medicine (Diabetes), Newcastle University, Newcastle upon Tyne, United Kingdom., McDonald TJ; NIHR Exeter Clinical Research Facility, University of Exeter Medical School and Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom., Perry MH; Department of Blood Sciences, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom., De Masi F; Department of Bio and Health Informatics, Technical University of Denmark, Kongens Lyngby, Denmark., Brunak S; Department of Bio and Health Informatics, Technical University of Denmark, Kongens Lyngby, Denmark.; Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Mahajan A; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom., Giordano GN; Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Malmö, Sweden., Kokkola T; Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland., Dermitzakis E; Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland.; Institute of Genetics and Genomics in Geneva (iGE3), University of Geneva, Geneva, Switzerland.; Swiss Institute of Bioinformatics, Geneva, Switzerland., Viñuela A; Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland.; Institute of Genetics and Genomics in Geneva (iGE3), University of Geneva, Geneva, Switzerland.; Swiss Institute of Bioinformatics, Geneva, Switzerland., Pedersen O; The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Schwenk JM; Affinity Proteomics, Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH-Royal Institute of Technology, Solna, Sweden., Adamski J; Research Unit Molecular Endocrinology and Metabolism, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, Neuherberg, Germany.; Lehrstuhl für Experimentelle Genetik, Technische Universität München, Freising-Weihenstephan, Germany.; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Teare HJA; HeLEX, Nuffield Department of Population Health, University of Oxford, Headington, Oxford, United Kingdom., Pearson ER; Division of Population Health & Genomics, School of Medicine, University of Dundee, Dundee, United Kingdom., Franks PW; Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Malmö, Sweden.; Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, Oxford, United Kingdom.; Department of Nutrition, Harvard School of Public Health, Boston, MA, United States of America., 't Hart LM; Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam University Medical Centre, Location VU University Medical Center, Amsterdam, The Netherlands.; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Biomedical Data Sciences, Molecular Epidemiology Section, Leiden University Medical Center, Leiden, The Netherlands., Rutters F; Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam University Medical Centre, Location VU University Medical Center, Amsterdam, The Netherlands.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2020 Nov 30; Vol. 15 (11), pp. e0242360. Date of Electronic Publication: 2020 Nov 30 (Print Publication: 2020).
DOI: 10.1371/journal.pone.0242360
Abstrakt: Aim: Subclasses of different glycaemic disturbances could explain the variation in characteristics of individuals with type 2 diabetes (T2D). We aimed to examine the association between subgroups based on their glucose curves during a five-point mixed-meal tolerance test (MMT) and metabolic traits at baseline and glycaemic deterioration in individuals with T2D.
Methods: The study included 787 individuals with newly diagnosed T2D from the Diabetes Research on Patient Stratification (IMI-DIRECT) Study. Latent class trajectory analysis (LCTA) was used to identify distinct glucose curve subgroups during a five-point MMT. Using general linear models, these subgroups were associated with metabolic traits at baseline and after 18 months of follow up, adjusted for potential confounders.
Results: At baseline, we identified three glucose curve subgroups, labelled in order of increasing glucose peak levels as subgroup 1-3. Individuals in subgroup 2 and 3 were more likely to have higher levels of HbA1c, triglycerides and BMI at baseline, compared to those in subgroup 1. At 18 months (n = 651), the beta coefficients (95% CI) for change in HbA1c (mmol/mol) increased across subgroups with 0.37 (-0.18-1.92) for subgroup 2 and 1.88 (-0.08-3.85) for subgroup 3, relative to subgroup 1. The same trend was observed for change in levels of triglycerides and fasting glucose.
Conclusions: Different glycaemic profiles with different metabolic traits and different degrees of subsequent glycaemic deterioration can be identified using data from a frequently sampled mixed-meal tolerance test in individuals with T2D. Subgroups with the highest peaks had greater metabolic risk.
Competing Interests: The authors have read the journal’s policy and have the following competing interests: IP is employed by Eli Lilly Regional Operations GmbH, Vienna, Austria and BJ and HR are employees of Sanofi-Aventis Deutschland GmbH, R&D, Frankfurt am Main, Germany. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje